{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:24:07Z","timestamp":1779377047253,"version":"3.53.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s11739-020-02624-5","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T02:40:10Z","timestamp":1610592010000},"page":"975-979","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Impact of combining vancomycin with piperacillin\/tazobactam or with meropenem on vancomycin-induced nephrotoxicity"],"prefix":"10.1007","volume":"16","author":[{"given":"R. F.","family":"Tookhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. A.","family":"Kabli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Huntul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-9094","authenticated-orcid":false,"given":"A. K.","family":"Thabit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"issue":"2","key":"2624_CR1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.amjmed.2009.05.031","volume":"123","author":"KA Hazlewood","year":"2010","unstructured":"Hazlewood KA, Brouse SD, Pitcher WD, Hall RG (2010) Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med 123(2):182. https:\/\/doi.org\/10.1016\/j.amjmed.2009.05.031","journal-title":"Am J Med"},{"issue":"7","key":"2624_CR2","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/aje\/kws273","volume":"177","author":"EY Klein","year":"2013","unstructured":"Klein EY, Sun L, Smith DL, Laxminarayan R (2013) The changing epidemiology of methicillin-resistant Staphylococcus aureus in the United States: a national observational study. Am J Epidemiol 177(7):666\u2013674. https:\/\/doi.org\/10.1093\/aje\/kws273","journal-title":"Am J Epidemiol"},{"issue":"4","key":"2624_CR3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1086\/600884","volume":"49","author":"TP Lodise","year":"2009","unstructured":"Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL (2009) Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 49(4):507\u2013514. https:\/\/doi.org\/10.1086\/600884","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2624_CR4","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/AAC.01568-12","volume":"57","author":"SJ van Hal","year":"2013","unstructured":"van Hal SJ, Paterson DL, Lodise TP (2013) Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 57(2):734\u2013744. https:\/\/doi.org\/10.1128\/AAC.01568-12","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2624_CR5","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/phar.1488","volume":"34","author":"JJ Carreno","year":"2014","unstructured":"Carreno JJ, Kenney RM, Lomaestro B (2014) Vancomycin-associated renal dysfunction: where are we now? Pharmacotherapy 34(12):1259\u20131268. https:\/\/doi.org\/10.1002\/phar.1488","journal-title":"Pharmacotherapy"},{"issue":"1","key":"2624_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/CCM.0000000000002769","volume":"46","author":"MK Luther","year":"2018","unstructured":"Luther MK, Timbrook TT, Caffrey AR, Dosa D, Lodise TP, LaPlante KL (2018) Vancomycin plus piperacillin\u2013tazobactam and acute kidney injury in adults: a systematic review and meta-analysis. Crit Care Med 46(1):12\u201320. https:\/\/doi.org\/10.1097\/CCM.0000000000002769","journal-title":"Crit Care Med"},{"issue":"6","key":"2624_CR7","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jiph.2016.11.007","volume":"10","author":"MS Al Yami","year":"2017","unstructured":"Al Yami MS (2017) Comparison of the incidence of acute kidney injury during treatment with vancomycin in combination with piperacillin\u2013tazobactam or with meropenem. J Infect Public Health 10(6):770\u2013773. https:\/\/doi.org\/10.1016\/j.jiph.2016.11.007","journal-title":"J Infect Public Health"},{"key":"2624_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1128\/AAC.00264-18","volume":"62","author":"WC Rutter","year":"2018","unstructured":"Rutter WC, Burgess DS (2018) Incidence of acute kidney injury among patients treated with piperacillin\u2013tazobactam or meropenem in combination with vancomycin. Antimicrob Agents Chemother 62:7. https:\/\/doi.org\/10.1128\/AAC.00264-18","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"2624_CR9","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/phar.1428","volume":"34","author":"DM Gomes","year":"2014","unstructured":"Gomes DM, Smotherman C, Birch A, Dupree L, Della Vecchia BJ, Kraemer DF, Jankowski CA (2014) Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin\u2013tazobactam or cefepime. Pharmacotherapy 34(7):662\u2013669. https:\/\/doi.org\/10.1002\/phar.1428","journal-title":"Pharmacotherapy"},{"key":"2624_CR10","volume-title":"MERREM\u00ae, meropenem for intravenous injection","author":"P Information","year":"2019","unstructured":"Information P (2019) MERREM\u00ae, meropenem for intravenous injection. AstraZeneca Inc, Wilmington, DE"},{"issue":"12","key":"2624_CR11","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/phar.2179","volume":"38","author":"AD Robertson","year":"2018","unstructured":"Robertson AD, Li C, Hammond DA, Dickey TA (2018) Incidence of acute kidney injury among patients receiving the combination of vancomycin with piperacillin\u2013tazobactam or meropenem. Pharmacotherapy 38(12):1184\u20131193. https:\/\/doi.org\/10.1002\/phar.2179","journal-title":"Pharmacotherapy"},{"key":"2624_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1128\/AAC.02658-18","volume":"63","author":"AM Blevins","year":"2019","unstructured":"Blevins AM, Lashinsky JN, McCammon C, Kollef M, Micek S, Juang P (2019) Incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin\u2013tazobactam, cefepime, or meropenem. Antimicrob Agents Chemother 63:5. https:\/\/doi.org\/10.1128\/AAC.02658-18","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2624_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1517\/14656566.2015.993381","volume":"16","author":"AK Thabit","year":"2015","unstructured":"Thabit AK, Crandon JL, Nicolau DP (2015) Antimicrobial resistance: Impact on clinical and economic outcomes and the need for new antimicrobials. Expert Opin Pharmacother 16(2):159\u2013177. https:\/\/doi.org\/10.1517\/14656566.2015.993381","journal-title":"Expert Opin Pharmacother"},{"key":"2624_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1189","author":"SN Avedissian","year":"2019","unstructured":"Avedissian SN, Pais GM, Liu J, Rhodes NJ, Scheetz MH (2019) Piperacillin\u2013tazobactam added to vancomycin increases risk for AKI: fact or fiction? Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciz1189","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2624_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.1","volume":"2","author":"JA Kellum","year":"2012","unstructured":"Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, Herzog CA, Joannidis M, Kribben A, Levey AS, MacLeod AM, Mehta RL, Murray PT, Naicker S, Opal SM, Schaefer F, Schetz M, Uchino S (2012) Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2(1):1\u2013138. https:\/\/doi.org\/10.1038\/kisup.2012.1","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"2624_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/0897190016628960","volume":"30","author":"V Peyko","year":"2017","unstructured":"Peyko V, Smalley S, Cohen H (2017) Prospective comparison of acute kidney injury during treatment with the combination of piperacillin\u2013tazobactam and vancomycin versus the combination of cefepime or meropenem and vancomycin. J Pharm Pract 30(2):209\u2013213. https:\/\/doi.org\/10.1177\/0897190016628960","journal-title":"J Pharm Pract"},{"issue":"23","key":"2624_CR17","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1056\/NEJM196812052792302","volume":"279","author":"DS Baldwin","year":"1968","unstructured":"Baldwin DS, Levine BB, McCluskey RT, Gallo GR (1968) Renal failure and interstitial nephritis due to penicillin and methicillin. N Engl J Med 279(23):1245\u20131252. https:\/\/doi.org\/10.1056\/NEJM196812052792302","journal-title":"N Engl J Med"},{"issue":"6","key":"2624_CR18","doi-asserted-by":"publisher","first-page":"e0217908","DOI":"10.1371\/journal.pone.0217908","volume":"14","author":"S Kang","year":"2019","unstructured":"Kang S, Park J, Yu YM, Park MS, Han E, Chang MJ (2019) Comparison of acute kidney injury and clinical prognosis of vancomycin monotherapy and combination therapy with beta-lactams in the intensive care unit. PLoS ONE 14(6):e0217908. https:\/\/doi.org\/10.1371\/journal.pone.0217908","journal-title":"PLoS ONE"},{"key":"2624_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz563","author":"GM Pais","year":"2020","unstructured":"Pais GM, Liu J, Avedissian SN, Hiner D, Xanthos T, Chalkias A, d\u2019Aloja E, Locci E, Gilchrist A, Prozialeck WC, Rhodes NJ, Lodise TP, Fitzgerald JC, Downes KJ, Zuppa AF, Scheetz MH (2020) Lack of synergistic nephrotoxicity between vancomycin and piperacillin\/tazobactam in a rat model and a confirmatory cellular model. J Antimicrob Chemother. https:\/\/doi.org\/10.1093\/jac\/dkz563","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2624_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/ckj\/sfz158","volume":"13","author":"BJ Girling","year":"2020","unstructured":"Girling BJ, Channon SW, Haines RW, Prowle JR (2020) Acute kidney injury and adverse outcomes of critical illness: correlation or causation? Clin Kidney J 13(2):133\u2013141. https:\/\/doi.org\/10.1093\/ckj\/sfz158","journal-title":"Clin Kidney J"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-020-02624-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-020-02624-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-020-02624-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T04:39:34Z","timestamp":1623386374000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-020-02624-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["2624"],"URL":"https:\/\/doi.org\/10.1007\/s11739-020-02624-5","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,13]]},"assertion":[{"value":"21 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Biomedical Ethics Committee of the Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia (reference No. 500-18).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"For this type of study, no informed consent was required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}